RBC Capital Markets Lowers Philips Q1 Outlook Amid Tariff Headwinds
RBC Capital Markets analysts have issued a research note predicting that Royal Philips's first-quarter results will face incremental tariff headwinds, likely causing sales growth and profitability to fall slightly below consensus estimates. The Dutch medical-technology firm is scheduled to report next month. Analysts forecast like-for-like sales growth of 3.1% (excluding currency changes) against a consensus of 3.3%, and an adjusted Ebita margin of 8.2% versus the expected 8.3%. Key factors contributing to this cautious outlook include tariff challenges, more normalized growth in personal health product sales within China, and a longer lag time for converting diagnosis-and-treatment orders into revenue. Following the release of this analysis, Philips shares rose by 4.3%. This update is part of the Wall Street Journal's Health Care Roundup Market Talk series.
Wire timeline
RBC Capital Markets Lowers Philips Q1 Outlook Amid Tariff Headwinds
RBC Capital Markets analysts have issued a research note predicting that Royal Philips's first-quarter results will face incremental tariff headwinds, likely causing sales growth and profitability to fall slightly below consensus estimates. The Dutch medical-technology firm is scheduled to report next month. Analysts forecast like-for-like sales growth of 3.1% (excluding currency changes) against a consensus of 3.3%, and an adjusted Ebita margin of 8.2% versus the expected 8.3%. Key factors contributing to this cautious outlook include tariff challenges, more normalized growth in personal health product sales within China, and a longer lag time for converting diagnosis-and-treatment orders into revenue. Following the release of this analysis, Philips shares rose by 4.3%. This update is part of the Wall Street Journal's Health Care Roundup Market Talk series.
WSJ.com: Markets